August 28, 2012
Eli Lilly Japan announced on August 24 that its attention-deficit/hyperactivity disorder (ADHD) treatment Strattera (atomoxetine) received on the same day approval for an additional indication of ADHD in adults aged 18 and older. Strattera is the first drug approved for...read more